- Stocks
- Pharma & Healthcare
- Asarfi Hospital
Asarfi Hospital share price
NSE: ASARFIPharma & HealthcareMedical Care Facilities
Asarfi Hospital at a glance
With a market capitalisation of ₹446 Cr, it ranks 1853rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
Its return on equity was 17.1% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹45 Cr (+33.5% year on year) and net profit ₹4 Cr (+9.2%), on a consolidated basis. Promoters held 61.17% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹446 CrRank 1853 on NSE
- Price to book
- 3.42×FY26
- EPS (TTM)
- ₹8.47to Q4 FY26
- ROE
- 17.1%FY26
- ROCE
- 18.4%FY26
- Debt to equity
- 0.59FY26
- Net profit margin
- 9.6%FY26
- Book value / share
- ₹49.62FY26
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Asarfi Hospital quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹23 Cr | ₹31 Cr | ₹33 Cr | ₹34 Cr | ₹36 Cr | ₹45 Cr | ₹46 Cr | ₹45 Cr |
| Revenue YoY | — | — | +64.0% | +41.0% | +55.7% | +45.5% | +40.2% | +33.5% |
| Net profit | ₹1 Cr | ₹3 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹4 Cr | ₹5 Cr | ₹4 Cr |
| Net profit YoY | — | — | — | — | +115.2% | +47.4% | +102.2% | +9.2% |
| Net margin | 6.3% | 9.2% | 8.1% | 10.6% | 8.7% | 9.4% | 11.8% | 8.7% |
| EPS | ₹0.74 | ₹1.45 | ₹1.36 | ₹1.82 | ₹1.59 | ₹2.13 | ₹2.76 | ₹1.99 |
Asarfi Hospital financials
| Item | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹84 Cr | ₹121 Cr | — |
| Operating profit | ₹6 Cr | ₹14 Cr | — |
| Net profit | ₹4 Cr | ₹11 Cr | — |
| EPS (₹) | ₹2.00 | ₹5.00 | — |
| Cash from operations | ₹26 Cr | −₹4 Cr | — |
| Total debt | ₹20 Cr | ₹34 Cr | ₹35 Cr |
| Shareholders' equity | ₹70 Cr | ₹81 Cr | ₹98 Cr |
Asarfi Hospital shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 61.17% | 61.17% | 61.17% | 61.17% | 61.17% | 61.17% |
| Domestic institutions | 2.92% | 3.18% | 2.19% | 1.98% | 2.40% | 2.97% |
| Non-institutions | 35.91% | 35.55% | 36.59% | 36.85% | 36.43% | 35.86% |
Asarfi Hospital vs peers
The listed Pharma & Healthcare companies nearest to Asarfi Hospital by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| PREVESTPrevest Denpro | — | — | — | ₹472 Cr | — | — |
| HALEOSLABSHALEOS LABS | ₹1,540.00 | +0.59% | +36.5% | ₹466 Cr | 26.9 | — |
| ALBERTDAVDAlbert David | ₹795.00 | −3.90% | −0.6% | ₹454 Cr | — | — |
| ASARFIAsarfi Hospital | — | — | — | ₹446 Cr | — | — |
| JENBURPHJenburkt Pharma | ₹905.20 | −1.63% | — | ₹399 Cr | 11.5 | — |
| TRANSCHEMTranschem | — | — | — | ₹391 Cr | — | — |
| APPLAptus Pharma | — | — | — | ₹377 Cr | — | — |
Ask anything about Asarfi Hospital
Pivot answers on the live chart with evidence you can check, and tests strategies against ASARFI's own history. Try: “Why has ASARFI moved over the last three months?” · “Backtest a 50-day moving-average crossover on ASARFI over five years” · “Compare ASARFI with PREVEST on margins and valuation”
Frequently asked questions about Asarfi Hospital
What is the market cap of Asarfi Hospital?
Asarfi Hospital's market capitalisation is ₹446 Cr (₹446 Cr) at the 19 Oct 2026 close, ranking 1853rd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Asarfi Hospital?
Return on equity was 17.1% in FY26 and return on capital employed was 18.4% in FY26 (consolidated figures).
Is Asarfi Hospital a debt-free company?
No. Asarfi Hospital's debt-to-equity ratio was 0.59 in FY26, with total debt of ₹35 Cr.
What were Asarfi Hospital's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Asarfi Hospital reported revenue of ₹45 Cr, +33.5% year on year, and net profit of ₹4 Cr, +9.2% year on year.
What is the shareholding pattern of Asarfi Hospital?
As of 30 Jun 2026: promoters 61.17%, domestic institutions 2.97%, non-institutions 35.86%.
Who are Asarfi Hospital's competitors?
The listed Pharma & Healthcare companies closest to Asarfi Hospital by market cap are Prevest Denpro, HALEOS LABS, Albert David, Jenburkt Pharma, Transchem and Aptus Pharma.
Is Asarfi Hospital a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Asarfi Hospital's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ASARFI against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text